396 related articles for article (PubMed ID: 21232047)
21. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
22. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
23. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
24. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
Rennard SI; Sun SX; Tourkodimitris S; Rowe P; Goehring UM; Bredenbröker D; Calverley PM
Int J Chron Obstruct Pulmon Dis; 2014; 9():657-73. PubMed ID: 25018629
[TBL] [Abstract][Full Text] [Related]
25. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Reid DJ; Pham NT
Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
[TBL] [Abstract][Full Text] [Related]
26. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Sinopal'nikov AI
Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
[TBL] [Abstract][Full Text] [Related]
27. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
Karish SB; Gagnon JM
Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
29. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
30. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacological profile of roflumilast].
Cortijo Gimeno J; Morcillo Sánchez E
Arch Bronconeumol; 2010 Dec; 46 Suppl 10():19-24. PubMed ID: 21316552
[TBL] [Abstract][Full Text] [Related]
32. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
Giembycz MA; Newton R
Clin Chest Med; 2014 Mar; 35(1):203-17. PubMed ID: 24507847
[TBL] [Abstract][Full Text] [Related]
33. The use of roflumilast in COPD: a primary care perspective.
Price D; Chisholm A; Ryan D; Crockett A; Jones R
Prim Care Respir J; 2010 Dec; 19(4):342-51. PubMed ID: 21085915
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
[TBL] [Abstract][Full Text] [Related]
35. Roflumilast: A Review in COPD.
Garnock-Jones KP
Drugs; 2015 Sep; 75(14):1645-56. PubMed ID: 26338438
[TBL] [Abstract][Full Text] [Related]
36. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
Field SK
Expert Opin Investig Drugs; 2008 May; 17(5):811-8. PubMed ID: 18447606
[TBL] [Abstract][Full Text] [Related]
37. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.
Diamant Z; Spina D
Pulm Pharmacol Ther; 2011 Aug; 24(4):353-60. PubMed ID: 21255672
[TBL] [Abstract][Full Text] [Related]
38. Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen LF; Lv XD; Chen WY; Yang Q; Fang ZX; Lu WF
Ir J Med Sci; 2018 Aug; 187(3):731-738. PubMed ID: 29397527
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
[TBL] [Abstract][Full Text] [Related]
40. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
